Columnist Caroline Gainer weighs in on how changes with her doctors have affected her ability to coordinate care for her COPD ...

Fatigue is one of the most common symptoms of COPD, so it's important to understand what causes it, columnist Caroline Gainer ...

Digital inhalers that allow remote patient monitoring may predict impending exacerbations, or episodes when symptoms of COPD ...

Predicting COPD exacerbations In a pilot study, Drummond and his colleagues examined whether the ProAir Digihaler can help predict an impending COPD exacerbation. The researchers remotely enrolled 55 ...

Yupelri (revefenacin) is an approved once-daily maintenance therapy developed by Theravance Biopharma and Mylan (now part of Viatris) for chronic obstructive pulmonary disease (COPD). Its U.S.

COPD News Today is strictly a news and information website about the disease. It does not provide medical advice, diagnosis or treatment. This content is not intended to be a substitute for ...

It is sold as Spiriva HandiHaler, a dry powder inhaler approved in 2004, or as Spiriva Respimat, an inhalation spray approved in 2014. The Phase 4 trial — a type of study conducted after a medication ...

The Verona Pharma therapy, with a list price of $2,950 for a monthly supply, was cleared by the U.S. Food and Drug Administration in June as an inhaled maintenance therapy for adults with COPD. “We ...

While the risk of COPD was highest among traditional cigarette smokers and dual users, e-cigarette users also had a significantly increased risk of COPD over people who’d never used e-cigarettes or ...

Benralizumab (MEDI-563) is an investigational subcutaneous injection therapy for the treatment of asthma and COPD. It was studied in two Phase 3 trials, but the results showed that it failed to lower ...